'A usterity' ranks high among the buzz words most widely used in recent times but, especially in healthcare, 'innovation' follows close behind. NHS England has been accused of conflating the two -for example, Sustainability and Transformation Plans in the NHS became a way to bring trusts within budget 1 -and there is a whiff of that in a proposed joint venture with NICE that aims to deliver innovative medicines without breaking the bank.
The two organisations are consulting on changing NICE's technology appraisal process and NHS England's highly specialised technologies programmes.
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In short, they are hoping to offer quick NHS access for cheap medicines, relief for NHS England from its obligation to provide early funding for expensive new approvals, and a smoother uptake of medicines for very rare disorders.
Pressure for change
The pharmaceutical industry has long complained that the NHS does not use its new products quickly enough. It points out that the UK ranks ninth out of 13 comparable countries for uptake of new medicines in 16 therapeutic classes and, five years after a product is introduced, uptake in the UK is 40% below that of other countries. 3 The NICE approval process is among the "significant barriers" that deprive the NHS of modern medicines, the pharmaceutical industry believes. It was this kind of thinking that brought about the Cancer Drugs Fund as a way of circumventing the evidence-based appraisal process by which NHS spending on medicines is, in effect, rationed. But neither the Department of Health nor NHS England could quantify the Fund's impact on patient outcomes or say whether the money was well spent. 4 Better, then, to change the way NICE does its work. The Department of Health commissioned the Accelerated Access Review to find ways to "speed up access to innovative drugs, devices, diagnostics and digital products to NHS patients". 5 The gist of its 18 recommendations is that potentially "transformative" new technologies should be designated for fast track approval and their journey to the bedside should be facilitated by incentives and streamlined procedures with active support from NHS England and a new Accelerated Access Unit.
Pledging NHS England's full support, chief executive Simon Stevens pointed to the elephant in the room, noting: "We have no choice other than to drive value and affordability across the NHS if we're going to create headroom for faster and wider uptake of important new patient treatments."
NICE fast track process
This proposed variant of the appraisal process will fast track technologies (see Figure 1 ) for which there is strong evidence that the cost per quality-adjusted life year (QALY) gained would be £10,000 or less (rather than the £20,000-£30,000 range that currently represents value for money). Between 2007 and 2014, about 15 per cent of NICE-recommended technologies fell below this new threshold. Drug companies will apply for entry to the procedure and NICE will aim to issue guidance by the time licensing approval is recommended to the European Medicines Agency. The normal appraisal time of 43 weeks will be cut to 32 weeks by avoiding some consultation and review, based on the principle that the strength of evidence supporting the product has already been recognised.
Cash limits
NICE currently considers the impact of its recommendations on NHS spending as part of the appraisal process. In future, a positive appraisal recommendation will depend on cost effectiveness alone and the purpose of the budget impact estimate will be to determine the need for price negotiations between NHS England and drug companies.
Funding will be guaranteed for NICErecommended technologies that are likely to cost up to £20 million annually in the first three years -within 90 days as standard and within 30 days for fast tracked technologies. NICE says 80 per cent of the technologies recommended between 2015 and 2016 fell below this threshold.
When the £20 million budget impact threshold is exceeded, the drug company and NHS England will have three months to negotiate a patient access scheme. If they fail, NHS England will be able to ask for "a longer period of phased introduction" for the new technology. It is clear that NICE and NHS England are united on the need to ensure money and staff are available to introduce recommended technologies without disrupting existing services.
Highly specialised technologies
NICE and NHS England want to align their separate appraisal and commissioning procedures for drugs to treat very rare disorders. NICE will extend its value-for-money threshold to £100,000 per QALY gained. Medicines with a cost-effectiveness ratio below this threshold would be funded automatically, provided their estimated budget impact falls below the £20 million annual limit. Drugs with higher costeffectiveness ratios would be considered under the current system for specialised commissioning prioritisation; those exceeding the budget impact limit would be subject to further negotiation, as for nonspecialised technologies.
Summary
NICE and NHS England are proposing faster, easier access to the NHS for some new technologies in return for a limit on their budget impact. The consultation process ran from October 2016 to Januar y 2017, and is now closed. NICE is currently reviewing all comments and working on amendments to the proposals, with the aim of implementing them by April 2017.
